JP2020011980A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020011980A5 JP2020011980A5 JP2019172295A JP2019172295A JP2020011980A5 JP 2020011980 A5 JP2020011980 A5 JP 2020011980A5 JP 2019172295 A JP2019172295 A JP 2019172295A JP 2019172295 A JP2019172295 A JP 2019172295A JP 2020011980 A5 JP2020011980 A5 JP 2020011980A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- composition according
- agent
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021152652A JP2022000445A (ja) | 2009-11-13 | 2021-09-17 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26114909P | 2009-11-13 | 2009-11-13 | |
| US61/261,149 | 2009-11-13 | ||
| JP2017206911A JP2018076300A (ja) | 2009-11-13 | 2017-10-26 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017206911A Division JP2018076300A (ja) | 2009-11-13 | 2017-10-26 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021152652A Division JP2022000445A (ja) | 2009-11-13 | 2021-09-17 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020011980A JP2020011980A (ja) | 2020-01-23 |
| JP2020011980A5 true JP2020011980A5 (enExample) | 2020-04-16 |
| JP7317650B2 JP7317650B2 (ja) | 2023-07-31 |
Family
ID=43618172
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538994A Active JP5931736B2 (ja) | 2009-11-13 | 2010-11-12 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2016000552A Active JP6235620B2 (ja) | 2009-11-13 | 2016-01-05 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2017206911A Pending JP2018076300A (ja) | 2009-11-13 | 2017-10-26 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2019172295A Active JP7317650B2 (ja) | 2009-11-13 | 2019-09-20 | Ｈｅｒ－３関連疾患を治療または予防するための物質および方法 |
| JP2021152652A Pending JP2022000445A (ja) | 2009-11-13 | 2021-09-17 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012538994A Active JP5931736B2 (ja) | 2009-11-13 | 2010-11-12 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2016000552A Active JP6235620B2 (ja) | 2009-11-13 | 2016-01-05 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
| JP2017206911A Pending JP2018076300A (ja) | 2009-11-13 | 2017-10-26 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021152652A Pending JP2022000445A (ja) | 2009-11-13 | 2021-09-17 | Ｈｅｒ−３関連疾患を治療または予防するための物質および方法 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9101760B2 (enExample) |
| EP (5) | EP3351558B1 (enExample) |
| JP (5) | JP5931736B2 (enExample) |
| KR (1) | KR101806323B1 (enExample) |
| CN (2) | CN102812045B (enExample) |
| AR (1) | AR080564A1 (enExample) |
| AU (1) | AU2010319483B2 (enExample) |
| BR (1) | BR112012012160B1 (enExample) |
| CA (1) | CA2780935C (enExample) |
| CY (2) | CY1119751T1 (enExample) |
| DK (2) | DK3351558T3 (enExample) |
| ES (3) | ES2655737T3 (enExample) |
| HK (1) | HK1207651A1 (enExample) |
| HR (2) | HRP20180104T1 (enExample) |
| HU (2) | HUE049880T2 (enExample) |
| LT (2) | LT2719708T (enExample) |
| MX (3) | MX357972B (enExample) |
| NO (1) | NO2719708T3 (enExample) |
| PL (2) | PL2719708T3 (enExample) |
| PT (2) | PT3351558T (enExample) |
| RS (2) | RS56741B1 (enExample) |
| SI (2) | SI3351558T1 (enExample) |
| SM (2) | SMT201800167T1 (enExample) |
| TW (1) | TWI630916B (enExample) |
| UY (1) | UY33034A (enExample) |
| WO (1) | WO2011060206A2 (enExample) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108421044A (zh) | 2005-02-03 | 2018-08-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| BRPI0618042A2 (pt) | 2005-11-04 | 2011-08-16 | Wyeth Corp | usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| US8669273B2 (en) | 2008-08-04 | 2014-03-11 | Wyeth Llc | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine |
| US8921314B2 (en) | 2008-10-15 | 2014-12-30 | Angiochem, Inc. | Conjugates of GLP-1 agonists and uses thereof |
| SG10201402742YA (en) | 2009-03-20 | 2014-08-28 | Genentech Inc | Bispecific anti-her antibodies |
| IL264349B2 (en) | 2009-04-06 | 2024-01-01 | Wyeth Llc | Regimen comprising neratinib for the treatment of cancer |
| CA2775601C (en) | 2009-09-28 | 2017-10-03 | Qilu Pharmaceutical Co., Ltd | 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors |
| ES2860453T3 (es) | 2009-10-30 | 2021-10-05 | Novartis Ag | Bibliotecas universales del dominio de unión del lado inferior de la fibronectina de tipo III |
| AU2015201262B2 (en) * | 2009-11-13 | 2017-04-27 | Amgen Inc. | Material and methods for treating or preventing her-3 associated diseases |
| BR112012012160B1 (pt) * | 2009-11-13 | 2022-04-26 | Amgen, Inc. | Material e métodos para tratar ou prevenir doenças associadas ao her-3 |
| PH12012501157A1 (en) | 2009-12-22 | 2012-10-29 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| MX345300B (es) | 2010-07-30 | 2017-01-24 | Novartis Ag * | Moléculas andamio de fibronectina y bibliotecas de las mismas. |
| SG187908A1 (en) | 2010-08-20 | 2013-03-28 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| KR101862832B1 (ko) | 2010-11-01 | 2018-05-30 | 심포젠 에이/에스 | Ｐａｎ―ｈｅｒ 항체 조성물 |
| US9273143B2 (en) | 2011-09-30 | 2016-03-01 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody |
| PH12014500483A1 (en) | 2011-09-30 | 2014-04-14 | Regeneron Pharma | Anti-erbb3 antibodies and uses thereof |
| JP2015504038A (ja) | 2011-10-31 | 2015-02-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 低減した免疫原性を有するフィブロネクチン結合ドメイン |
| MX350957B (es) | 2011-11-23 | 2017-09-27 | Medimmune Llc | Moleculas de union especificas para her3 y usos de las mismas. |
| KR102083957B1 (ko) * | 2011-12-05 | 2020-03-04 | 노파르티스 아게 | 표피 성장 인자 수용체 3 (her3)에 대한 항체 |
| TW201331225A (zh) * | 2011-12-05 | 2013-08-01 | Novartis Ag | 針對表皮生長因子受體３（ｈｅｒ３）之域ｉｉｉ及域ｉｖ之ｈｅｒ３抗體 |
| US20150037336A1 (en) * | 2012-02-22 | 2015-02-05 | U3 Pharma Gmbh | Combination of hb-egf binding protein and egfr inhibitor |
| CN108404129A (zh) * | 2012-02-23 | 2018-08-17 | 第三共欧洲有限公司 | 用于调节放射敏感性的her3抑制剂 |
| HK1202431A1 (en) | 2012-05-02 | 2015-10-02 | Symphogen A/S | Humanized pan-her antibody compositions |
| EP2885321A4 (en) * | 2012-08-14 | 2016-03-30 | Angiochem Inc | CONJUGATES WITH AN ANTIBODY PART, A POLYPEPTIDE THROUGH THE BLOOD BRAIN BARRIER, AND A CYTOTOXIN |
| EP2727942A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Bispecific antibodies against human EGFR, HER2, and HER3 |
| EP2727943A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Trispecific antibodies against human EGFR, HER2 and HER3 |
| EP2914629A1 (en) | 2012-11-05 | 2015-09-09 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| EP2727941A1 (en) | 2012-11-05 | 2014-05-07 | MAB Discovery GmbH | Method for the production of multispecific antibodies |
| RU2015121818A (ru) * | 2012-11-12 | 2017-01-10 | Ангиохем Инк. | Конъюгаты антител с полипептидами-производными апротинина |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| WO2015048008A2 (en) | 2013-09-24 | 2015-04-02 | Medimmune, Llc | Binding molecules specific for her3 and uses thereof |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| CN111228511B (zh) * | 2014-04-10 | 2024-06-18 | 第一三共株式会社 | 抗her3抗体-药物偶联物 |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| WO2016038610A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki) |
| WO2016038609A1 (en) * | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| CN104861068B (zh) * | 2015-01-23 | 2020-11-17 | 中国人民解放军军事科学院军事医学研究院 | 一种全人源抗her3抗体及其治疗相关疾病的用途 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| US10980892B2 (en) | 2015-06-15 | 2021-04-20 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| CN116059395A (zh) | 2015-06-29 | 2023-05-05 | 第一三共株式会社 | 用于选择性制造抗体-药物缀合物的方法 |
| WO2017102789A1 (en) * | 2015-12-17 | 2017-06-22 | F. Hoffmann-La Roche Ag | Combination therapy of anti-her3 antibodies and anti-her2 antibodies |
| DK3512886T3 (da) * | 2016-09-15 | 2025-08-18 | Univ Stuttgart | Antigenbindingsprotein mod her3 |
| EP3552626A4 (en) | 2016-12-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | ASSOCIATION OF AN ANTIBODY DRUG CONJUGATE AND AN IMMUNE CONTROL POINT INHIBITOR |
| EP3572428A4 (en) | 2017-01-17 | 2020-12-30 | Daiichi Sankyo Company, Limited | ANTI-BODY ANTI-GPR20 AND ANTI-BODY-DRUG CONJUGATE ANTI-GPR20 |
| WO2018159582A1 (ja) * | 2017-02-28 | 2018-09-07 | 学校法人近畿大学 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｅｇｆｒ－ｔｋｉ抵抗性の非小細胞肺癌の治療方法 |
| WO2018201016A1 (en) | 2017-04-28 | 2018-11-01 | Cascadian Therapeutics, Inc. | Treatment of her2 positive cancers |
| TWI855528B (zh) | 2017-05-15 | 2024-09-11 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
| KR20250084239A (ko) | 2017-08-31 | 2025-06-10 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 개량 제조 방법 |
| JP7248578B2 (ja) | 2017-08-31 | 2023-03-29 | 第一三共株式会社 | 抗体－薬物コンジュゲートの新規製造方法 |
| HRP20240756T1 (hr) | 2018-05-18 | 2024-09-13 | Daiichi Sankyo Co., Ltd. | Anti-muc1-eksatekan antitijelo-lijek konjugat |
| JP2021534811A (ja) * | 2018-06-22 | 2021-12-16 | シーアールディー ファーマシューティカルズ インコーポレイティド | 抗ｈｅｒ３抗体およびその用途 |
| TWI846717B (zh) | 2018-07-27 | 2024-07-01 | 日商第一三共股份有限公司 | 辨識抗體-藥物結合物之藥物部位的蛋白質 |
| EP3831412A4 (en) | 2018-07-31 | 2022-04-27 | Daiichi Sankyo Company, Limited | TREATMENT OF METASTATIC BRAIN TUMOR BY ADMINISTRATION OF AN ANTIBODY-DRUG CONJUGATE |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| EP4096781A1 (en) | 2020-01-28 | 2022-12-07 | RefleXion Medical, Inc. | Joint optimization of radionuclide and external beam radiotherapy |
| KR20240153994A (ko) * | 2022-03-03 | 2024-10-24 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | Her3 결합 단백질 및 그의 용도 |
| US20250281631A1 (en) * | 2022-04-29 | 2025-09-11 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd | Antibody-drug conjugates and preparation methods and use thereof |
Family Cites Families (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1467383A (en) | 1974-06-12 | 1977-03-16 | Farmaceutici Italia | Daunomycin analogues |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399276A (en) | 1981-01-09 | 1983-08-16 | Kabushiki Kaisha Yakult Honsha | 7-Substituted camptothecin derivatives |
| US4471052A (en) | 1982-01-18 | 1984-09-11 | Adria Laboratories, Inc. | Biosynthesis of simplified anthracyclines |
| JPS58166633A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
| JPS58166634A (ja) | 1982-03-29 | 1983-10-01 | Toshiba Corp | 有機溶媒電池用正極 |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| JPS62170639A (ja) | 1986-01-22 | 1987-07-27 | 株式会社システムメンテナンス | 防蟻板の取付け工法 |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) * | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US4939168A (en) | 1989-08-11 | 1990-07-03 | Harbor Branch Oceanographics Institution, Inc. | Discodermolide compounds, compositions containing same and methods of preparation and use |
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| WO1992022670A1 (en) | 1991-06-12 | 1992-12-23 | Genpharm International, Inc. | Early detection of transgenic embryos |
| WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2135313A1 (en) | 1992-06-18 | 1994-01-06 | Theodore Choi | Methods for producing transgenic non-human animals harboring a yeast artificial chromosome |
| ES2301158T3 (es) | 1992-07-24 | 2008-06-16 | Amgen Fremont Inc. | Produccion de anticuerpos xenogenicos. |
| US5981175A (en) | 1993-01-07 | 1999-11-09 | Genpharm Internation, Inc. | Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome |
| AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2129288C (en) | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
| US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
| AU697142B2 (en) * | 1993-11-23 | 1998-10-01 | Genentech Inc. | Protein tyrosine kinases named Rse |
| FR2718135B1 (fr) | 1994-04-05 | 1996-04-26 | Rhone Poulenc Rorer Sa | Procédé de préparation d'hydroxy-7 taxanes. |
| FR2721928A1 (fr) | 1994-07-04 | 1996-01-05 | Rhone Poulenc Rorer Sa | Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5643763A (en) * | 1994-11-04 | 1997-07-01 | Genpharm International, Inc. | Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating |
| TW321649B (enExample) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| US5837815A (en) * | 1994-12-15 | 1998-11-17 | Sugen, Inc. | PYK2 related polypeptide products |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US6150581A (en) * | 1995-06-07 | 2000-11-21 | United States Surgical Corporation | Chitosan/alginate anti-adhesion barrier |
| CA2230759C (en) | 1995-08-29 | 2012-02-21 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for producing the same |
| US5681847A (en) | 1995-12-05 | 1997-10-28 | Harbor Branch Oceanographic Institution, Inc. | Methods of using discodermolide compounds |
| AU727082B2 (en) | 1996-03-27 | 2000-11-30 | Genentech Inc. | ErbB3 antibodies |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US6114595A (en) * | 1996-04-11 | 2000-09-05 | The Procter & Gamble Company | Stretchable, extensible composite topsheet for absorbent articles |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6204388B1 (en) | 1996-12-03 | 2001-03-20 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| JP2001505779A (ja) | 1996-12-11 | 2001-05-08 | スージェン・インコーポレーテッド | Ｐｙｋ２関連産物および方法 |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| KR100851418B1 (ko) | 1998-11-20 | 2008-08-08 | 코산 바이오사이언시즈, 인코포레이티드 | 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질 |
| AU2209899A (en) | 1998-12-30 | 2000-07-24 | Sugen, Inc. | Pyk2 (raftk) and inflammation |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| AUPQ105799A0 (en) * | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| AT500848B1 (de) | 1999-06-25 | 2008-01-15 | Genentech Inc | Humanisierte anti-erbb2-antikörper |
| PL202369B1 (pl) | 1999-08-27 | 2009-06-30 | Genentech Inc | Zastosowanie przeciwciała skierowanego przeciw ErbB2, zastosowanie przeciwciała skierowanego przeciw ErbB oraz zestaw zawierający to przeciwciało |
| FR2817258B1 (fr) * | 2000-11-27 | 2003-01-10 | Atofina | Procede de sulfochloration photochimique d'alcanes gazeux |
| IL152420A0 (en) | 2001-02-23 | 2003-05-29 | Novartis Ag | Novel oncolytic adenoviral vectors |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| ATE443259T1 (de) | 2001-09-20 | 2009-10-15 | Univ Texas | Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests |
| EP3698626A1 (en) | 2001-11-30 | 2020-08-26 | Amgen Fremont Inc. | Transgenic animals bearing human ig lambda light chain genes |
| ATE374944T1 (de) | 2001-12-03 | 2007-10-15 | Abgenix Inc | Identifizierung hochaffiner moleküle durch screening mit begrenzter verdünnung |
| CN1219882C (zh) | 2002-03-18 | 2005-09-21 | 上海泽生科技开发有限公司 | 以erbb－3为基础的用于肿瘤治疗的方法和组合物 |
| US7919098B2 (en) | 2002-03-26 | 2011-04-05 | Zensun ( Shanghai ) Sci & Tech Co., Ltd. | ErbB-3 based methods and compositions for treating neoplasms |
| US7332580B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| JP4443407B2 (ja) | 2002-07-25 | 2010-03-31 | アクララ バイオサイエンシーズ， インコーポレイテッド | レセプターオリゴマー形成の検出 |
| ATE472556T1 (de) | 2002-12-02 | 2010-07-15 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
| EP1613732A4 (en) | 2003-04-01 | 2012-03-14 | Monogram Biosciences Inc | INTRA-CELLULAR COMPLEXES AS BIOMARKERS |
| JP2005024385A (ja) | 2003-07-02 | 2005-01-27 | Matsushita Electric Ind Co Ltd | 感圧センサ |
| ES2710439T3 (es) * | 2005-01-21 | 2019-04-25 | Genentech Inc | Dosificación fija de anticuerpos HER |
| CN101160403B (zh) | 2005-02-18 | 2014-08-13 | 安吉奥开米公司 | 转运化合物穿过血脑屏障的分子 |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| BRPI0520530A2 (pt) * | 2005-10-05 | 2009-09-29 | Astrazeneca Uk Ltd | método para predizer ou monitorar a resposta de um paciente a uma droga receptora do erbb |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| SG178789A1 (en) * | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| GB0706633D0 (en) * | 2007-04-04 | 2007-05-16 | Cyclacel Ltd | Combination |
| PE20090368A1 (es) * | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| UY31800A (es) * | 2008-05-05 | 2009-11-10 | Smithkline Beckman Corp | Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb |
| EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| KR20120059568A (ko) * | 2009-08-21 | 2012-06-08 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ３의 엑토도메인에 대한 항체 및 이의 용도 |
| BR112012012160B1 (pt) * | 2009-11-13 | 2022-04-26 | Amgen, Inc. | Material e métodos para tratar ou prevenir doenças associadas ao her-3 |
| JP7372920B2 (ja) | 2017-12-29 | 2023-11-01 | セレクティス | Ｃａｒ ｔ細胞の作製を改良するための方法 |
-
2010
- 2010-11-12 BR BR112012012160-0A patent/BR112012012160B1/pt active IP Right Grant
- 2010-11-12 AU AU2010319483A patent/AU2010319483B2/en active Active
- 2010-11-12 LT LTEP13189092.3T patent/LT2719708T/lt unknown
- 2010-11-12 EP EP17197711.9A patent/EP3351558B1/en active Active
- 2010-11-12 SI SI201032011T patent/SI3351558T1/sl unknown
- 2010-11-12 NO NO13189092A patent/NO2719708T3/no unknown
- 2010-11-12 PT PT171977119T patent/PT3351558T/pt unknown
- 2010-11-12 EP EP20151640.8A patent/EP3670539A1/en active Pending
- 2010-11-12 RS RS20180048A patent/RS56741B1/sr unknown
- 2010-11-12 MX MX2016002120A patent/MX357972B/es unknown
- 2010-11-12 MX MX2012005589A patent/MX349513B/es active IP Right Grant
- 2010-11-12 LT LTEP17197711.9T patent/LT3351558T/lt unknown
- 2010-11-12 PT PT131890923T patent/PT2719708T/pt unknown
- 2010-11-12 ES ES13189092.3T patent/ES2655737T3/es active Active
- 2010-11-12 EP EP13189092.3A patent/EP2719708B1/en active Active
- 2010-11-12 HU HUE17197711A patent/HUE049880T2/hu unknown
- 2010-11-12 PL PL13189092T patent/PL2719708T3/pl unknown
- 2010-11-12 ES ES15154165.3T patent/ES2647466T3/es active Active
- 2010-11-12 KR KR1020127015255A patent/KR101806323B1/ko active Active
- 2010-11-12 EP EP10785251A patent/EP2499162A2/en not_active Withdrawn
- 2010-11-12 HU HUE13189092A patent/HUE035605T2/en unknown
- 2010-11-12 CN CN201080052236.XA patent/CN102812045B/zh active Active
- 2010-11-12 RS RS20200651A patent/RS60390B1/sr unknown
- 2010-11-12 ES ES17197711T patent/ES2781299T3/es active Active
- 2010-11-12 PL PL17197711T patent/PL3351558T3/pl unknown
- 2010-11-12 SM SM20180167T patent/SMT201800167T1/it unknown
- 2010-11-12 SI SI201031627T patent/SI2719708T1/en unknown
- 2010-11-12 TW TW099139038A patent/TWI630916B/zh active
- 2010-11-12 DK DK17197711.9T patent/DK3351558T3/da active
- 2010-11-12 WO PCT/US2010/056430 patent/WO2011060206A2/en not_active Ceased
- 2010-11-12 CA CA2780935A patent/CA2780935C/en active Active
- 2010-11-12 SM SM20200267T patent/SMT202000267T1/it unknown
- 2010-11-12 EP EP15154165.3A patent/EP2896632B1/en active Active
- 2010-11-12 US US12/944,764 patent/US9101760B2/en active Active
- 2010-11-12 MX MX2016008205A patent/MX358013B/es unknown
- 2010-11-12 DK DK13189092.3T patent/DK2719708T3/da active
- 2010-11-12 CN CN201610373755.5A patent/CN105999263B/zh active Active
- 2010-11-12 JP JP2012538994A patent/JP5931736B2/ja active Active
- 2010-11-15 UY UY33034A patent/UY33034A/es not_active Application Discontinuation
- 2010-11-15 AR ARP100104211 patent/AR080564A1/es unknown
-
2013
- 2013-04-25 US US13/870,796 patent/US9803025B2/en active Active
-
2015
- 2015-08-20 HK HK15108089.8A patent/HK1207651A1/en unknown
-
2016
- 2016-01-05 JP JP2016000552A patent/JP6235620B2/ja active Active
- 2016-01-18 US US15/000,005 patent/US9988462B2/en active Active
-
2017
- 2017-10-26 JP JP2017206911A patent/JP2018076300A/ja active Pending
- 2017-10-27 US US15/796,361 patent/US12139549B2/en active Active
- 2017-12-13 CY CY20171101305T patent/CY1119751T1/el unknown
-
2018
- 2018-01-19 HR HRP20180104TT patent/HRP20180104T1/hr unknown
-
2019
- 2019-09-20 JP JP2019172295A patent/JP7317650B2/ja active Active
-
2020
- 2020-06-05 CY CY20201100505T patent/CY1123030T1/el unknown
- 2020-06-08 HR HRP20200921TT patent/HRP20200921T1/hr unknown
-
2021
- 2021-09-17 JP JP2021152652A patent/JP2022000445A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200921T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih sa her-3 | |
| JP2013510868A5 (enExample) | ||
| JP2018508512A5 (enExample) | ||
| Ballantyne et al. | Trastuzumab emtansine: first global approval | |
| RU2010135585A (ru) | Моноклональные антитела для лечения опухолей | |
| JP2011512332A5 (enExample) | ||
| JP2008531576A5 (enExample) | ||
| JP2018536632A5 (ja) | Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子 | |
| JP2016520082A5 (enExample) | ||
| JP2020055853A5 (enExample) | ||
| JP2013520442A5 (enExample) | ||
| JP2022058802A5 (enExample) | ||
| JP2017533912A5 (enExample) | ||
| JP2008503476A5 (enExample) | ||
| JP2012509889A5 (enExample) | ||
| JP2022058676A (ja) | Ｌｉｖ１－ａｄｃ及び化学療法剤を用いた併用療法 | |
| FI3223848T3 (fi) | Menetelmiä käyttää bispesifisiä antigeenia sitovia rakenteita, jotka kohdistuvat her2:een | |
| RU2018111529A (ru) | Комбинированная терапия для лечения рака | |
| Lindenblatt et al. | Paclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model | |
| JP2023512196A5 (enExample) | ||
| Khayat et al. | Taxol in the management of cancers of the breast and the ovary | |
| RU2010151602A (ru) | Комбинированная терапия с помощью рм00104 и другого противоопухолевого средства | |
| JP2022512851A5 (enExample) | ||
| MX2024014345A (es) | Conjugados de anticuerpo-farmaco de compuestos antineoplasicos y metodos de uso de los mismos | |
| JP2025507817A5 (enExample) |